Nifty
:
23349.90
Sensex
:
77155.79
-168.60 (-0.72%)
-422.59 (-0.54%)
Nifty
Sensex
:
:
23349.90
77155.79
-168.60 (-0.72%)
-422.59 (-0.54%)

Strides Pharma Science Ltd.

Pharmaceuticals & Drugs - Global

Rating :
N/A

BSE: 532531 | NSE: STAR

NSE BSE
936.45
05-Jul-2024
  • Open
  • High
  • Low
  • Previous Close
  •  953.10
  •  964.80
  •  931.00
  •  950.40
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  156186
  •  1478.22
  •  1675.00
  •  482.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 13,977.65
  • 55.38
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 16,017.52
  • 0.16%
  • 5.64

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 25.84%
  • 3.15%
  • 18.57%
  • FII
  • DII
  • Others
  • 30.08%
  • 16.67%
  • 5.69%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.98
  • 6.33
  • 9.68

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.35
  • 7.52
  • 26.41

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -18.90
  • -11.45
  • -35.27

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 6.52
  • -
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.24
  • 2.24
  • 2.34

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.50
  • 16.27
  • 18.51

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Net Sales
1,201.11
999.43
20.18%
1,087.50
929.99
16.94%
1,084.04
986.37
9.90%
1,037.67
864.85
19.98%
Expenses
965.30
846.30
14.06%
870.52
763.40
14.03%
854.30
830.81
2.83%
843.86
748.50
12.74%
EBITDA
235.81
153.13
53.99%
216.98
166.59
30.25%
229.73
155.56
47.68%
193.81
116.34
66.59%
EBIDTM
19.63%
15.32%
19.95%
17.91%
21.19%
15.77%
18.68%
13.45%
Other Income
28.41
35.85
-20.75%
12.72
8.64
47.22%
-13.55
27.12
-
8.75
26.20
-66.60%
Interest
82.15
78.59
4.53%
80.39
76.42
5.19%
80.16
80.52
-0.45%
79.28
58.44
35.66%
Depreciation
50.52
60.10
-15.94%
48.59
59.59
-18.46%
49.76
60.93
-18.33%
51.23
60.22
-14.93%
PBT
127.67
-114.64
-
96.98
33.25
191.67%
78.20
33.89
130.75%
61.99
65.44
-5.27%
Tax
21.20
-7.44
-
16.86
9.68
74.17%
19.25
7.09
171.51%
10.10
4.09
146.94%
PAT
106.47
-107.20
-
80.12
23.57
239.92%
58.95
26.81
119.88%
51.88
61.35
-15.44%
PATM
8.86%
-10.73%
7.37%
2.53%
5.44%
2.72%
5.00%
7.09%
EPS
10.14
-14.54
-
7.64
-0.77
-
1.98
-1.06
-
5.41
-8.86
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
4,410.32
4,051.12
3,688.39
3,070.25
3,315.87
2,981.12
3,108.33
3,344.37
3,826.22
2,862.19
1,195.85
Net Sales Growth
16.66%
9.83%
20.13%
-7.41%
11.23%
-4.09%
-7.06%
-12.59%
33.68%
139.34%
 
Cost Of Goods Sold
1,755.84
1,640.50
1,626.88
1,502.32
1,332.79
1,122.48
1,085.20
1,378.84
1,281.17
1,502.29
560.49
Gross Profit
2,654.48
2,410.62
2,061.50
1,567.93
1,983.08
1,858.64
2,023.14
1,965.53
2,545.05
1,359.90
635.37
GP Margin
60.19%
59.51%
55.89%
51.07%
59.81%
62.35%
65.09%
58.77%
66.52%
47.51%
53.13%
Total Expenditure
3,533.98
3,318.01
3,303.09
3,091.76
2,689.06
2,470.90
2,811.65
3,108.66
3,309.30
2,481.62
967.00
Power & Fuel Cost
-
86.47
85.82
71.54
64.58
64.49
54.39
51.33
33.87
77.18
16.02
% Of Sales
-
2.13%
2.33%
2.33%
1.95%
2.16%
1.75%
1.53%
0.89%
2.70%
1.34%
Employee Cost
-
751.13
732.02
646.91
550.15
442.56
329.44
434.05
419.16
357.69
172.06
% Of Sales
-
18.54%
19.85%
21.07%
16.59%
14.85%
10.60%
12.98%
10.95%
12.50%
14.39%
Manufacturing Exp.
-
314.63
259.45
255.52
237.94
210.79
150.98
115.97
137.47
119.23
41.37
% Of Sales
-
7.77%
7.03%
8.32%
7.18%
7.07%
4.86%
3.47%
3.59%
4.17%
3.46%
General & Admin Exp.
-
253.44
232.21
223.67
191.73
191.89
150.10
194.38
172.63
198.71
86.25
% Of Sales
-
6.26%
6.30%
7.29%
5.78%
6.44%
4.83%
5.81%
4.51%
6.94%
7.21%
Selling & Distn. Exp.
-
224.81
263.65
331.30
223.22
137.07
111.22
208.85
161.12
129.57
61.37
% Of Sales
-
5.55%
7.15%
10.79%
6.73%
4.60%
3.58%
6.24%
4.21%
4.53%
5.13%
Miscellaneous Exp.
-
47.02
103.06
60.51
88.65
301.61
930.33
725.25
1,103.88
96.95
61.37
% Of Sales
-
1.16%
2.79%
1.97%
2.67%
10.12%
29.93%
21.69%
28.85%
3.39%
2.46%
EBITDA
876.33
733.11
385.30
-21.51
626.81
510.22
296.68
235.71
516.92
380.57
228.85
EBITDA Margin
19.87%
18.10%
10.45%
-0.70%
18.90%
17.12%
9.54%
7.05%
13.51%
13.30%
19.14%
Other Income
36.33
49.85
135.22
133.40
59.44
66.70
322.90
920.64
398.08
102.37
38.57
Interest
321.98
314.44
261.14
176.74
150.06
155.72
79.29
196.24
183.10
168.17
47.44
Depreciation
200.10
220.68
243.25
233.01
206.29
187.79
171.85
193.93
198.69
131.25
64.03
PBT
364.84
247.84
16.11
-297.88
329.90
233.42
368.44
766.17
533.20
183.50
155.95
Tax
67.41
31.59
-55.30
-178.26
31.65
17.91
14.49
21.41
51.19
42.45
147.60
Tax Rate
18.48%
53.72%
6010.87%
32.91%
8.48%
11.50%
3.71%
2.96%
10.30%
29.87%
99.35%
PAT
297.42
-124.83
-221.20
-460.21
352.32
143.62
370.31
681.31
399.38
113.21
1.57
PAT before Minority Interest
302.22
-148.53
-230.90
-474.25
341.61
137.82
375.57
701.18
445.58
99.68
0.98
Minority Interest
4.80
23.70
9.70
14.04
10.71
5.80
-5.26
-19.87
-46.20
13.53
0.59
PAT Margin
6.74%
-3.08%
-6.00%
-14.99%
10.63%
4.82%
11.91%
20.37%
10.44%
3.96%
0.13%
PAT Growth
6,465.56%
-
-
-
145.31%
-61.22%
-45.65%
70.59%
252.78%
7,110.83%
 
EPS
32.33
-13.57
-24.04
-50.02
38.30
15.61
40.25
74.06
43.41
12.31
0.17

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
2,125.56
2,212.26
2,359.23
2,776.66
2,527.42
2,648.70
2,463.66
2,748.82
2,657.87
1,144.92
Share Capital
91.90
90.30
89.79
89.68
89.56
89.55
89.50
89.42
89.35
59.62
Total Reserves
2,030.57
2,102.54
2,266.99
2,682.26
2,432.13
2,551.59
2,365.10
2,650.55
2,562.75
1,084.50
Non-Current Liabilities
621.44
1,210.30
965.72
1,264.45
813.65
2,342.88
2,067.29
2,048.67
2,760.03
285.79
Secured Loans
618.40
1,040.81
744.86
873.43
601.79
1,806.45
1,551.09
1,622.87
2,614.88
250.23
Unsecured Loans
53.10
98.98
90.77
9.15
2.12
0.06
0.23
14.84
12.13
17.16
Long Term Provisions
91.63
73.42
64.28
246.50
63.95
52.24
16.55
25.19
14.45
6.02
Current Liabilities
2,879.26
2,990.20
3,411.68
2,738.35
2,544.86
2,662.24
1,899.30
3,103.87
1,891.98
1,019.94
Trade Payables
851.59
982.34
1,071.52
1,134.20
797.75
888.99
712.07
774.09
775.40
234.41
Other Current Liabilities
341.57
527.89
697.18
421.00
354.49
248.12
129.98
819.08
347.93
502.47
Short Term Borrowings
1,574.15
1,330.76
1,496.53
1,023.84
1,228.78
1,339.02
944.39
1,393.96
700.48
203.03
Short Term Provisions
111.94
149.20
146.43
159.31
163.84
186.11
112.86
116.73
68.19
80.03
Total Liabilities
5,572.40
6,373.38
6,760.72
6,816.80
5,953.17
7,806.77
6,584.90
8,034.86
7,360.09
2,469.36
Net Block
1,853.18
2,298.42
2,333.45
2,151.13
2,025.85
3,570.13
2,903.00
2,909.03
2,678.68
701.36
Gross Block
2,873.18
3,324.82
3,231.69
2,841.28
2,534.38
4,049.05
3,229.03
3,186.12
2,825.43
1,080.55
Accumulated Depreciation
1,020.00
1,026.40
898.24
690.15
508.53
478.92
326.03
277.09
146.75
379.19
Non Current Assets
2,603.41
3,130.03
3,398.88
3,999.57
3,581.05
4,758.05
4,101.31
4,243.05
3,845.20
1,039.91
Capital Work in Progress
161.89
150.98
291.08
447.37
412.95
453.03
620.29
780.18
814.88
171.17
Non Current Investment
196.93
438.96
540.34
666.23
503.24
494.34
350.08
315.66
127.19
68.76
Long Term Loans & Adv.
256.13
217.18
210.58
185.80
210.82
223.69
197.22
222.56
201.83
96.72
Other Non Current Assets
123.38
11.91
10.26
549.04
428.19
16.86
30.72
15.62
22.62
1.91
Current Assets
2,969.00
3,135.25
3,361.83
2,817.23
2,372.11
3,048.72
2,483.59
3,791.82
3,514.89
1,429.44
Current Investments
105.76
50.84
0.00
99.41
118.97
284.75
311.48
1,279.54
1,213.76
561.29
Inventories
1,126.24
1,146.51
1,173.80
1,200.70
782.54
874.16
552.02
732.80
613.14
207.68
Sundry Debtors
1,141.87
1,299.40
1,207.30
1,110.59
931.69
987.18
882.18
995.91
1,032.97
389.96
Cash & Bank
191.17
315.96
187.35
179.76
237.10
516.65
303.33
329.48
311.59
146.88
Other Current Assets
403.96
169.21
647.90
98.22
301.81
385.98
434.59
454.09
343.44
123.64
Short Term Loans & Adv.
174.97
153.34
145.49
128.54
218.24
249.11
295.75
244.39
97.54
54.46
Net Current Assets
89.74
145.05
-49.84
78.89
-172.75
386.48
584.29
687.95
1,622.91
409.50
Total Assets
5,572.41
6,265.28
6,760.71
6,816.80
5,953.16
7,806.77
6,584.90
8,034.87
7,360.09
2,469.35

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
701.07
44.41
-257.81
481.44
204.79
60.05
187.07
288.14
73.25
83.40
PBT
-62.72
-267.63
-652.51
289.38
48.51
344.37
705.80
497.14
146.44
992.01
Adjustment
818.27
682.19
582.27
363.31
527.49
94.59
-274.51
190.92
345.56
-756.73
Changes in Working Capital
-78.73
-457.80
-189.90
-328.05
-326.23
-323.14
-190.66
-341.30
-341.71
-95.91
Cash after chg. in Working capital
676.82
-43.23
-260.14
324.64
249.76
115.82
240.63
346.76
150.29
139.37
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
24.25
87.64
2.33
156.80
-44.98
-55.76
-53.56
-58.62
-77.04
-55.97
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-150.25
302.47
-118.73
-520.82
1,306.16
-148.49
582.59
-686.69
-2,224.83
51.87
Net Fixed Assets
-75.44
-54.00
-61.59
-86.75
-167.06
-48.49
677.20
-236.66
-535.93
-66.57
Net Investments
-6.57
-92.01
62.72
-219.57
-17.15
-383.09
747.64
-143.27
-1,478.58
78.09
Others
-68.24
448.48
-119.86
-214.50
1,490.37
283.09
-842.25
-306.76
-210.32
40.35
Cash from Financing Activity
-693.32
-213.92
421.32
-15.80
-1,709.45
194.27
-1,015.69
338.21
2,943.94
-421.25
Net Cash Inflow / Outflow
-142.51
132.96
44.77
-55.18
-198.50
105.83
-246.03
-60.33
792.35
-285.98
Opening Cash & Equivalents
303.50
170.73
125.83
182.23
365.89
256.16
515.08
1,110.74
298.91
586.00
Closing Cash & Equivalent
161.02
303.50
170.73
125.83
182.23
365.89
256.16
515.08
1,110.74
298.42

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
230.95
242.83
262.48
309.09
281.55
294.94
274.26
306.41
296.83
191.91
ROA
-2.49%
-3.52%
-6.99%
5.35%
2.00%
5.22%
9.59%
5.79%
2.03%
0.04%
ROE
-6.88%
-10.15%
-18.49%
12.91%
5.34%
14.74%
27.00%
16.53%
5.25%
0.09%
ROCE
4.15%
-0.49%
-9.49%
11.17%
6.01%
8.65%
16.07%
10.75%
7.54%
10.92%
Fixed Asset Turnover
2.02
1.91
1.75
2.04
1.50
1.17
1.04
1.27
1.47
1.21
Receivable days
71.28
73.25
79.41
68.09
70.88
79.95
102.49
96.77
90.73
114.71
Inventory Days
66.36
67.80
81.35
66.13
61.20
61.00
70.11
64.20
52.34
58.37
Payable days
204.02
230.40
267.95
264.54
138.58
146.59
116.23
117.33
75.51
76.81
Cash Conversion Cycle
-66.38
-89.35
-107.20
-130.32
-6.50
-5.64
56.37
43.64
67.55
96.27
Total Debt/Equity
1.14
1.27
1.18
0.76
0.78
1.22
1.03
1.35
1.34
0.78
Interest Cover
0.63
-0.10
-2.69
3.49
2.00
5.92
4.68
3.71
1.85
4.13

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Strides Pharma Science’s arm to acquire balance 30% stake in Strides Pharma International AG
    26th Oct 2024, 11:30 AM

    The acquisition marks a significant milestone in Strides' expansion efforts, further strengthening its position in the region

    Read More
  • Strides Pharma Science gets nod to invest Rs 1.61 crore in AMPIN C&I
    24th Oct 2024, 15:30 PM

    This project will facilitate harnessing solar energy at the company’s Alathur facility

    Read More
  • Strides Pharma Scien - Quarterly Results
    24th Oct 2024, 13:19 PM

    Read More
  • Strides Pharma Science’s arm gets USFDA’s approval for Fluoxetine Tabs
    16th Sep 2024, 15:30 PM

    The Fluoxetine tablets will be manufactured at the company’s facility in Puducherry

    Read More
  • Strides Pharma Science’ arm gets USFDA’s approval for Theophylline Extended-Release Tablets
    6th Sep 2024, 11:17 AM

    The Theophylline Extended-Release Tablets, 300 mg and 450 mg will be manufactured at the company’s flagship facility in KRS Gardens in Bangalore, India

    Read More
  • Strides Pharma Science’s arm gets EIR from USFDA
    19th Aug 2024, 10:42 AM

    USFDA has determined that the inspection classification of this facility is ‘Voluntary Action Indicated’

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.